Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zoetis Inc ZTS

Healthcare
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a... see more

Recent & Breaking News (NYSE:ZTS)

Zoetis Appoints American Express Executive Vice President and General Counsel, Louise Parent, to its Board of Directors

Business Wire August 1, 2013

Trial Results, New Facilities, Approved Labels, Spinoffs, and M&As Support Long-Term Growth Strategies - Research Report on Pfizer, Johnson & Johnson, Merck, Zoetis, and AstraZeneca

PR Newswire July 4, 2013

Zoetis Announces Plans to Expand Operations in Lincoln

Business Wire July 2, 2013

Zoetis to Host Webcast and Conference Call on Second-Quarter 2013 Financial Results

Business Wire June 28, 2013

Pfizer Announces Final Results of Zoetis Exchange Offer

Business Wire June 27, 2013

Nutrition - Pharma Stocks in the News: Embark Holdings, GNC, Vitamin Shoppe, Gilead Sciences, Pfizer

PR Newswire June 26, 2013

FDA Reviews, Acquisitions, Dividends, and Drug Study Results Highlight Solid Growth for Major Drug Companies - Research Report on Pfizer, Johnson & Johnson, Zoetis, AbbVie, and Lilly

PR Newswire June 26, 2013

Zoetis Becomes Fully Independent With Acceptance of Pfizer Shares Tendered in Exchange Offer

Business Wire June 24, 2013

Pfizer Announces Preliminary Results of Zoetis Exchange Offer and Adjusts 2013 Financial Guidance(1) Solely to Reflect Impact of Exchange Offer

Business Wire June 24, 2013

Zoetis(TM) Declares Third-Quarter 2013 Dividend

Business Wire June 20, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on CDXS, CLSN, MYGN and ZTS

Accesswire June 17, 2013

Zoetis Set to Join S&P 500; First Horizon National to Join S&P MidCap 400; QLogic to Join S&P SmallCap 600

PR Newswire June 14, 2013

TEVA, MYL, ZTS, COV, and VRX Under StockCall's Microscope

Accesswire June 14, 2013

Providing Quality Healthcare Through Long-term Investments, Divestitures, New Research, Clinical Trials Results - Research Report on AmerisourceBergen, Zoetis, AstraZeneca, Cardinal Health and Sanofi

PR Newswire June 12, 2013

Leading Investment Service Examines Recent IPOs and Spin-Offs

PR Newswire June 10, 2013

Zoetis To File Registration Statement; Comments on Pfizer's Split-off Plans for Remaining Interest in Zoetis

Business Wire May 22, 2013

Pfizer Announces Plan for Split-Off of Zoetis

Business Wire May 22, 2013

FDA Approves APOQUEL® (oclacitinib tablet) to Control Itch and Inflammation in Allergic Dogs

Business Wire May 16, 2013

Zoetis(TM) Reports First-Quarter 2013 Results

Business Wire April 30, 2013

Morning Research on Teva Pharma, Orexigen Therapeutics, Zoetis, and Novartis

PR Newswire April 3, 2013